Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 88 of 5804
-
New hope for older leukemia patients: targeted drug combo shows promise
Disease control OngoingThe safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free survival (EFS) and overall survival (OS) of participants receiving blinatumomab a…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New targeted therapy aims to outshine standard chemo for HER2-mutant lung cancer
Disease control OngoingDESTINY-Lung04 will investigate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) versus Standard of Care (SoC) as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) with HER2 Exon 19 or 20 mutations
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug combo aims to wipe out aggressive breast cancer before surgery
Disease control OngoingThis study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for rare Kidney-Blood disease: crovalimab trial shows promise
Disease control OngoingThis study aims to evaluate the efficacy and safety of crovalimab in adult and adolescent participants with aHUS.
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat pancreatic cancer
Disease control Recruiting nowThis clinical trial will evaluate the safety and activity of mutant KRAS G12V-specific TCR transduced T cell therapy for advanced pancreatic cancer patients who express the KRAS G12V mutation and HLA-A\*11:01 allele. The theoretical basis of this study is that mutant KRAS antigen…
Phase: PHASE1, PHASE2 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New hope for kids with deadly brain tumors: combination drug trial launches
Disease control Recruiting nowThis phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes for participants with DMGs, and there ar…
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug shows promise in Late-Stage breast cancer trial
Disease control OngoingThe study will evaluate the safety and efficacy of datopotamab deruxtecan (also known as Dato-DXd, DS-1062a), when compared with Investigator's choice of standard of care single-agent chemotherapy (eribulin, capecitabine, vinorelbine, or gemcitabine) in participants with inoperab…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Double-Drug attack on prostate cancer shows promise in early trial
Disease control OngoingThis randomized, placebo-controlled phase III trial is evaluating the benefit of rucaparib and enzalutamide combination therapy versus enzalutamide alone for the treatment of men with prostate cancer that has spread to other places in the body (metastatic) and has become resistan…
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Breakthrough drug could open door to kidney transplants for 'Impossible' patients
Disease control CompletedAn open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA ≥99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization using imlifidase with standard of care
Phase: PHASE3 • Sponsor: Hansa Biopharma AB • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New combo aims to stall return of blood cancer
Disease control OngoingThe purpose of this study is to compare the efficacy of teclistamab daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd) or daratumumab SC in combination with bortezomib and dexamethasone (DVd).
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Breakthrough hope: drug may stop epilepsy before it starts in TSC infants
Prevention Recruiting nowThis trial is a Phase II randomized, double-blind, placebo controlled multi-site study to evaluate the safety and efficacy of early sirolimus to prevent or delay seizure onset in TSC infants. This study is supported by research funding from the Office of Orphan Products Division…
Phase: PHASE2 • Sponsor: Darcy Krueger • Aim: Prevention
Last updated Jun 27, 2026 08:12 UTC
-
Can a new pill slow advanced breast cancer better than standard hormone therapy?
Disease control OngoingThe main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaciclib work compared to imlunestrant in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal …
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New hope for Tough-to-Treat myeloma: Two-Drug combo enters Late-Stage trial
Disease control Recruiting nowThe purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone, and (2) learn about the safet…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug aims to cut sickle cell pain episodes
Disease control CompletedThis Phase 3 study will assess the safety and efficacy of inclacumab, a P-selectin inhibitor, in reducing the frequency of vaso-occlusive crises (VOCs) in approximately 240 adult and adolescent participants (≥ 12 years of age) with sickle cell disease (SCD). Participants will be …
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Could a vaccine stop Triple-Negative breast cancer from coming back?
⭐️ VACCINE ⭐️ CompletedThe purpose of this study is to determine the safety as well as the most effective dose of the alpha-lactalbumin vaccine (aLA breast cancer vaccine) to treat patients with non-metastatic triple negative breast cancer, participants who are of cancer-free but may be at risk for tri…
Phase: EARLY_PHASE1 • Sponsor: George T. Budd • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 19, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat brain tumors
Disease control OngoingThe current design provides a window to analyze the impact of the ACT001+Pembrolizumab combination on the tumor microenvironment and disease outcomes.
Phase: PHASE1, PHASE2 • Sponsor: Accendatech USA Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Synthetic skin patch could revolutionize burn treatment
Disease control OngoingThis is a multi-center, pivotal study to assess the safety and effectiveness of a new method of treating severe burns using NovoSorb® Biodegradable Temporizing Matrix (BTM).
Phase: NA • Sponsor: PolyNovo Biomaterials Pty Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Immunotherapy combo shows promise in stomach cancer trial
Disease control CompletedA randomized, Double-blind, Multicenter, phase III Clinical Study of Comparing the Efficacy and Safety of AK104 Plus Oxaliplatin and Capecitabine (XELOX) Versus Placebo Plus XELOX as First-line Treatment for locally advanced Unresectable or Metastatic Gastric Adenocarcinoma or Ga…
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New blood test could spot lung cancer before it spreads
Diagnosis OngoingThis study is part of the development and validation of a non-invasive lung screening test which aim to identify early stage lung cancer in patients at high risk for lung cancer.
Sponsor: Nucleix Ltd. • Aim: Diagnosis
Last updated Jun 27, 2026 07:56 UTC
-
New drug cocktail shows promise against aggressive childhood cancer
Disease control OngoingThis phase III trial compares the safety and effect of adding vinorelbine to vincristine, dactinomycin, and cyclophosphamide (VAC) for the treatment of patients with high risk rhabdomyosarcoma (RMS). High risk refers to cancer that is likely to recur (come back) after treatment o…
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC